Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anti-amyloid drugs

- PMLiVE

AbbVie takes anti-tau drug into phase II for Alzheimer’s

Also testing antibody in rare condition PSP, for which FDA has awarded fast-track designation

- PMLiVE

Real-world evidence

Companies are now recruiting high-level executives to lead well-resourced RWE teams as industry looks to reshape the future

Deal Watch December 2016

Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up

AstraZeneca AZ

AZ tweaks immuno-oncology trials as it chases lung cancer leaders

Toughens targets for durvalumab in NSCLC monotherapy and combination study

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

Eli Lilly HQ

Lilly streamlines and culls leadership roles

Merges Europe and emerging markets interests and expands diabetes and oncology

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

Roche Basel Switzerland

Roche’s haemophilia A drug hits targets in registration trial

Emicizumab from Japanese affiliate Chugai cleared a phase III trial

Roche Basel Switzerland

FDA delays verdict on Roche’s MS drug Ocrevus

Additional manufacturing data postpones US verdict until 28 March 2017

Biogen Idec building

Biogen elevates Vounatsos to top seat

US biotech’s CCO to succeed George Scangos on 6 January

Eli Lilly HQ

Lilly nears EU approval of arthritis drug baricitinib

On course for early 2017 verdict, setting up challenge to Pfizer’s Xeljanz

Roche Basel Switzerland

Genentech names Anderson new CEO as Ian Clark retires

Leadership changes come as the Roche subsidiary faces increasing biologics competition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links